Drugs / TSG-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04515290 | May 2020 → Apr 2022 | heart failure | Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSG-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04515290 ↗ |
| Route | Oral | “were given by oral” NCT04515290 ↗ |